Detalhe da pesquisa
1.
Early intervention and disease modification in atopic dermatitis-the current state of the field and barriers to progress.
J Eur Acad Dermatol Venereol
; 38(4): 665-672, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38063244
2.
Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN.
J Eur Acad Dermatol Venereol
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38752592
3.
Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.
J Eur Acad Dermatol Venereol
; 37(9): 1863-1870, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184290
4.
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
J Eur Acad Dermatol Venereol
; 37(5): 976-983, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652273
5.
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.
J Eur Acad Dermatol Venereol
; 37(9): 1871-1880, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37247226
6.
Sickle cell bone disease and response to intravenous bisphosphonates in children.
Osteoporos Int
; 33(11): 2397-2408, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35904681
7.
Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
Br J Dermatol
; 186(3): 453-465, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34637142
8.
Pioneering global best practices in atopic dermatitis: results from the atopic dermatitis quality of care initiative.
Clin Exp Dermatol
; 47(2): 303-311, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34382243
9.
Employing the theory of planned behaviour to design an e-cigarette education resource for use in secondary schools.
BMC Public Health
; 22(1): 276, 2022 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35144592
10.
Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
J Eur Acad Dermatol Venereol
; 36(11): 2140-2152, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35695074
11.
Mass Equilibration and Fluctuations in the Angular Momentum Dependent Dynamics of Heavy Element Synthesis Reactions.
Phys Rev Lett
; 127(22): 222501, 2021 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34889627
12.
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Br J Dermatol
; 184(3): 437-449, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33000465
13.
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Br J Dermatol
; 185(1): 139-146, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33393074
14.
Measurement properties of patient-reported outcome measures for eczema control: a systematic review.
J Eur Acad Dermatol Venereol
; 35(10): 1987-1993, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33977561
15.
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
J Eur Acad Dermatol Venereol
; 35(2): 476-485, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926462
16.
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.
J Eur Acad Dermatol Venereol
; 35(2): 464-475, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32893393
17.
Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Br J Dermatol
; 182(1): 104-111, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30972740
18.
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
Br J Dermatol
; 182(6): e186-e209, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32476149
19.
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Br J Dermatol
; 182(5): 1120-1135, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31407311
20.
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Br J Dermatol
; 2020 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33179283